# ðŸ§ª Drugâ€“Indication Association Analysis (FAERS-derived data)

## Context
Understanding drugâ€“indication associations is an important component of healthcare and pharmaceutical data analysis.  
This project explores drugâ€“indication data extracted from the FDA Adverse Event Reporting System (FAERS) and standardized using clinical ontologies such as RxNorm, UMLS, and MONDO.

## Objective
To perform a descriptive and exploratory analysis of drugâ€“indication associations, focusing on data structure, coverage, and indication diversity across drugs.

This analysis does not aim to assess clinical effectiveness, safety, or causality.

## Data
The dataset contains drugâ€“indication associations derived from FAERS reports, including:
- Drug labels and synonyms
- RxNorm Clinical Unique Identifiers (RxCUI)
- Clinical indications mapped to UMLS and MONDO ontologies

## Methodology
- Data cleaning and parsing of multi-label drug and indication fields
- Explicit handling of missing indication data
- Exploratory data analysis (EDA)
- Analysis of indication distribution and drug indication profiles
- Visualization of key patterns

## Key findings
- A substantial proportion of drugs lack recorded indication information, reflecting dataset coverage limitations
- Most drugs with available data are associated with a small number of indications
- A limited subset of drugs shows broader indication profiles
- Drug labels required standardization to improve interpretability and visualization clarity

## Limitations
- Indications are derived from FAERS reports and do not represent treatment effectiveness or clinical outcomes
- Missing indication values reflect incomplete coverage rather than absence of clinical use
- Results are descriptive and should not be used for clinical or regulatory decision-making

## Tools
Python, Pandas, Matplotlib

## Disclaimer
This project uses publicly available data and is intended for educational and portfolio purposes only.
